Ep. 60 PARP Inhibitors: Clinical Trials & Real-World Applications with Dr. Neeraj Agarwal and Dr. Arun Azad episode artwork

EPISODE · May 19, 2026 · 1H 15M

Ep. 60 PARP Inhibitors: Clinical Trials & Real-World Applications with Dr. Neeraj Agarwal and Dr. Arun Azad

from BackTable Tumor Board · host BackTable Inc.

Keeping patients on PARP inhibitors long enough to see real benefit often comes down to proactive side effect management. In this episode of BackTable Urology, Dr. Neeraj Agarwal and Dr. Arun Azad join host Dr. Alan Tan to discuss practical, evidence-based strategies for managing hematologic and GI toxicities in advanced prostate cancer patients receiving PARP inhibitors. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction06:17 - Managing Anemia11:12 - Side Effect Profiles19:33 - Transfusions vs ESAs26:43 - Docetaxel vs PARP Inhibitors30:27 - Side Effect Management Pearls40:18 - Team Based Monitoring52:27 - Tissue Versus Liquid01:01:24 - Genetic Counseling Workflow01:07:07 - Trial Equity and Access --- More about this episode The doctors discuss the importance of close anemia monitoring during the critical first 3 to 4 months of therapy, maintaining dose intensity, proactive antiemetic use, and the role of exercise and resistance training in combating fatigue. The conversation also covers differences in toxicity profiles between PARP agents, the value of multidisciplinary care teams, molecular advances in molecular and germline testing, and the evolving landscape of emerging therapies in prostate care. ---Resources Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00684-1/abstract BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.19 --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Keeping patients on PARP inhibitors long enough to see real benefit often comes down to proactive side effect management. In this episode of BackTable Urology, Dr. Neeraj Agarwal and Dr. Arun Azad join host Dr. Alan Tan to discuss practical, evidence-based strategies for managing hematologic and GI toxicities in advanced prostate cancer patients receiving PARP inhibitors. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction06:17 - Managing Anemia11:12 - Side Effect Profiles19:33 - Transfusions vs ESAs26:43 - Docetaxel vs PARP Inhibitors30:27 - Side Effect Management Pearls40:18 - Team Based Monitoring52:27 - Tissue Versus Liquid01:01:24 - Genetic Counseling Workflow01:07:07 - Trial Equity and Access --- More about this episode The doctors discuss the importance of close anemia monitoring during the critical first 3 to 4 months of therapy, maintaining dose intensity, proactive antiemetic use, and the role of exercise and resistance training in combating fatigue. The conversation also covers differences in toxicity profiles between PARP agents, the value of multidisciplinary care teams, molecular advances in molecular and germline testing, and the evolving landscape of emerging therapies in prostate care. ---Resources Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00684-1/abstract BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.19 --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

NOW PLAYING

Ep. 60 PARP Inhibitors: Clinical Trials & Real-World Applications with Dr. Neeraj Agarwal and Dr. Arun Azad

0:00 1:15:29

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

API Intersection Stoplight Building a successful API requires more than just coding. It starts with collaborative design, focuses on creating a great developer experience, and ends with getting your company on board, maintaining consistency, and maximizing your API’s profitability.In the API Intersection, you’ll learn from experienced API practitioners who transformed their organizations, and get tangible advice to build quality APIs with collaborative API-first design.Jason Harmon brings over a decade of industry-recognized REST API experience to discuss topics around API design, governance, identity/auth versioning, and more.They’ll answer listener questions, and discuss best practices on API design (definition, modeling, grammar), Governance (multi-team design, reviewing new API’s), Platform Transformation (culture, internal education, versioning) and more.They’ll also chat with experienced API practitioners from a wide array of industries to draw out practical takeaways and insights you can use.H PDF feed of Interpreter: A Journal of Latter-day Saint Faith and Scholarship PDF feed of Interpreter: A Journal of Latter-day Saint Faith and Scholarship The Interpreter Foundation is a nonprofit educational organization focused on the scriptures of The Church of Jesus Christ of Latter-day Saints (the Book of Mormon, the Pearl of Great Price, the Bible, and the Doctrine and Covenants), early LDS history, and related subjects. All publications in its journal, Interpreter: A Journal of Latter-day Saint Faith and Scholarship, are peer-reviewed and made available as free internet downloads or through at-cost print-on-demand services. Other posts on the website are not necessarily peer-reviewed, but are approved by Interpreter’s Executive Board.Our goal is to increase understanding of scripture through careful scholarly investigation and analysis of the insights provided by a wide range of ancillary disciplines, including language, history, archaeology, literature, culture, ethnohistory, art, geography, law, politics, philosophy, statistics, etc. Interpreter will also publish articles advocating the authenticity and historicity Passive Investing Podcast The Real Estate Women The Passive Investing Podcast is a round table discussion where we teach you how to create a stream of passive income through Multi Family investing. Crystal, Candy, Colleen & Tamara dive into the classroom, board room and living room on Multi Family real estate investing, with Guests Matt Pichney, Rod Khleif, and Julie Holly pulling up a chair to share stories and insight on their areas of expertise. Whether you’re trying to jump into real estate to free yourself from the grind of the 9-5, to build a stream of passive income or to create generational wealth, join us at the table! Brasher Warning Brasher Warning Brasher Warning: Exploring the Skies, One Close Call at a Time: Take a deep dive into the intense world of aviation incidents with Brasher Warning, a podcast that explores the stories behind near misses, full-blown accidents, and everything in between. As a busy Chicago-based air traffic controller, husband, and father of two amazing girls, my time is limited, but my passion for aviation safety has never wavered. Thanks to cutting-edge AI, I’ve discovered a way to bring this passion back into my life—and now, into yours. Each episode unpacks real-life aviation events using detailed reports, including those from the National Transportation Safety Board (NTSB), weaving them into seamless, digestible narratives. Whether on my way to work, during a quick break, or while I’m getting ready for the day, AI allows me to analyze mountains of data and transform it into compelling stories that inform and entertain. And now I’m sharing that with you. Whether you’re an aviation enthusiast, a cur

Frequently Asked Questions

How long is this episode of BackTable Tumor Board?

This episode is 1 hour and 15 minutes long.

When was this BackTable Tumor Board episode published?

This episode was published on May 19, 2026.

What is this episode about?

Keeping patients on PARP inhibitors long enough to see real benefit often comes down to proactive side effect management. In this episode of BackTable Urology, Dr. Neeraj Agarwal and Dr. Arun Azad join host Dr. Alan Tan to discuss practical,...

Can I download this BackTable Tumor Board episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!